First Wave BioPharma Inc (FWBI)

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline

Nice month off the lows. I like it.

Nice month off the lows. I like it.

New pm highs

interesting turn in events.

Didn’t waste no time diluting

https://ih.advfn.com/stock-market/NASDAQ/first-wave-biopharma-FWBI/stock-news/92895157/form-s-1-a-general-form-for-registration-of-secu

S-1 killing this -9 from hi

Very true to form.

Back down in 2024

$FWBI NOV 2023 S-1 DILUTION Overall Risk
High
Offering Ability
High
Overhead Supply
High
Historical
High
Cash Need
High




https://dilutiontracker.com/app/search/FWBI

Trading soon

Fun

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173507523&txt2find=fwbi

GM bro! :)

NEW HIGHS FOR THIS MICRO FLOATER

FWBI NEWS https://www.globenewswire.com/news-release/2023/12/27/2801297/0/en/First-Wave-BioPharma-Announces-Streamlining-of-Clinical-Pipeline-with-Non-Binding-Term-Sheet-to-Sell-Niclosamide-IBD-Program.html

gm & thx

$FWBI
BOCA RATON, Fla

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and Adrulipase
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and related conditions to an undisclosed biopharmaceutical company (the “Proposed Transaction”). The Proposed Transaction will enable First Wave BioPharma to focus its development resources on its three late-stage clinical programs: Capeserod, a selective 5-HT4 receptor partial agonist licensed from Sanofi; Adrulipase, a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency (EPI); and, after the closing of the recently announced potential business combination with ImmunogenX, Latiglutenase, a Phase 3-ready oral biotherapeutic for celiac disease.

The non-binding term sheet includes a low seven-figure upfront payment to First Wave BioPharma for rights to Niclosamide, as well as economics related to future milestones and royalties. The transaction is expected to close in the first half of 2024. Additional details of the transaction will be disclosed upon finalization and execution of the definitive agreement. Upon execution of the definitive agreement, the completion of the transaction will be subject to, among other matters, satisfaction of the conditions negotiated therein, the buyer having secured adequate financing, and receipt of all third party (including governmental) approvals, licenses, consents, and clearances, as and when applicable.

“This is a very exciting time in the evolution of First Wave BioPharma as we have recently reinvigorated our GI-focused clinical development pipeline with Phase 2-ready Capeserod from Sanofi and the pending addition of Phase 3-ready Latiglutenase,” stated James Sapirstein, President and CEO of First Wave BioPharma. “We plan to rapidly advance these programs in 2024 given the significant potential of each to address GI conditions for which no effective therapies currently exist. As a result, we made the strategic decision to streamline our development pipeline and are pleased to have entered a non-binding term sheet for Niclosamide, which has the potential to infuse First Wave with additional, non-dilutive capital.”

Niclosamide is a prescription, non-systemic, small molecule drug listed as an essential medicine by the World Health Organization (WHO). Niclosamide was approved by the U.S. Food and Drug Administration (FDA) in 1982 for the treatment of intestinal tapeworm infections and has been safely used on millions of patients. The drug is a potential non-steroidal anti-inflammatory therapy for the treatment of mild-to-moderate inflammatory bowel diseases (IBD). First Wave BioPharma had previously conducted Phase 2 trials with niclosamide for the treatment of ulcerative proctitis/proctosigmoiditis (the most prevalent form of ulcerative colitis) and for the treatment of COVID gastrointestinal infections. The Company also has a Phase 2 open-IND for the treatment of immune checkpoint inhibitor-associated colitis and diarrhea in patients with metastatic cancer. Intellectual property for niclosamide formulations governing composition of matter and methods of use extends beyond 2040.

About First Wave BioPharma, Inc.

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical stage programs, including Capeserod, a selective 5-HT4 receptor partial agonist which First Wave is developing for gastrointestinal (GI) indications; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency; and it is anticipated that the Company will soon acquire Latiglutenase, a targeted, oral first-in-class biotherapeutic for celiac disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether a definitive agreement for the Proposed Transaction or a transaction with ImmunogenX and any concurrent financing or licensing transaction will be entered into; whether such transactions, or any other contemplated transaction, may be completed with different terms, in an untimely manner, or not at all; whether the Company will be able to realize the benefits of the Proposed Transaction described herein; the Company’s ability to integrate the assets and commercial operations contemplated to be acquired from ImmunogenX into the Company’s business; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able to maintain compliance with

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

Yes

did this recently do another r/s?

ATROCIOUS DUMPING

Fwbi .36

Run to dollars is on now.

Big conference presentation is tomorrow by the CEO.

This is the next big runner.

Price target: $11

Massively undervalued just like TPST.

Looks primed to run now

FWBI, Bad news: Financing at $0.43: LOL!

2023-09-14 10:44 ET - News Release
BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 5,882,036 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $0.43 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.0 million, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.

First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering
https://finance.yahoo.com/news/first-wave-biopharma-inc-announces-121500394.html

Common Stock Morgan Stanley
1 New York Plaza
38th Fl.
New York NY 10004
7,152,204 08/31/2023
Nasdaq


https://www.firstwavebio.com/tmp/dd1816af9e4e1e15974ac2972280ac3ba6d6202cefc0032c61d411270c518648.pdf

WOW STARTED BOUNCING EOD .57 THEN QUICK HARD DUMP TO .48


PRETTY SICK

HOW & WHY?

I DUNNO

YEP i LOST A CHUNK ON THIS ONE, GOT FOOLED THINKING THE BOTTOM WAS IN @ .60 AFTER HITTING 1.11

SOMETHING IS VERY WRONG EVEN IF THERE ARE 11M SHARES ADDED TO THE 7M THE HAD BEFORE THE WARRANTS

18M SHARES=12M=30M, THERE IS 128M VOLUME

THATS CLOSE TO 100M MORE = HOW IN THE WORLD>??????

AND BASICALLY NO BOUNCE

IVE SEEN SOME DO A "V" BOUNCE

THIS ONE IS A FLAT LINER

WHY I DO NOT KNOW

THE SANOFI NEWS IS SOLID

https://finance.yahoo.com/news/first-wave-biopharma-announces-exclusive-100000787.html

FWBI: No wonder I trashed this crap months ago! (The IDENTICAL routine; but this time they gots a REAL CONTRACT???? To SELL their insider SHARES???)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172121453

The fact algo’s allowed this to get above a buck today is just as mind boggling when lets be honest they knew a offering was coming

Unfortunately…..They don’t care about mom n pop traders

Big boys on wallstreet make money they satisfied

how the sec and nasdaq dont halt these crime scenes is mind boggling

I mean just look at the chart. This isn’t shocking….

boca raton based crooked ceo..figures

Not "back in", but for the FIRST time today, Bro --- since I too suspect that this could be that late market soaring freak show routine!

I might just get back in

They let it rise to $1.11 only to release this news bunch of crooks

just another pump and dump i see...thanks.

there is NO SEC to protect investors anymore.

FWBI: Grab this RIGHT NOW --- better yet was circa 30-minutes ago --- and you will likely DOUBLE your bet by the Close today!!

ITS MIND BOGGLING HOW THEY HAD 7M SHARES AND IT WENT TO 1.11

THEN 11M WARRANTS TAKE IT DOWN TO .59

THE FREAKIN VOLUME IS 10X THAT

SMH

Its the way it is on all these biopharma stocks. I saw this Premarket moving... in at .75 set a sell at .85. It happened in a blink. Watching it go up to 1.11 I was kicking myself but not anymore!!

$FWBI

FWBI: Well then, CONGRATS, Boss!!! How much you SCORE today on this one??? INSPIRE US!!!

Sincerely yours,

"That Nut Job"
San Diego, CA

A SHORTERS DREAM SITUATION POP OVER $1 ON HYPE PUMP, THEN SLASH & CRASH, WITH THE HELP OF COMPANY NEWS

WELCOME THE THE THUNDER DOME

FWBI: I need their stuff, RIGHT NOW!!!! (I could be a 'Control Group' of just one guy!!)

PS: If whomever does NOT like my humor, well, then EAT-SHIT-&-DIE!!!! (And then see if some Stinky Pinky Company has a VACCINE for that kind of self-inflicted DISEASE!!!)

ding ding ding

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market